



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_26676
Title of the Manuscript:	Immunotherapy as a Future Treatment for Relapsed and Metastatic Primary Pulmonary Sarcomas
Type of the Article	Commentary

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	The manuscript entitled "Immunotherapy as a Future Treatment for Relapsed and Metastatic Primary Pulmonary Sarcomas" covers different immunotherapy approaches that could be applied for the treatment of PPS. It would be helpful for the readers if the author also includes some of the controversies/pitfalls on using any of these approaches in the treatment of PPS.	Thank you, I will be sure to include the information that pertains to the difficulties in treatment. Surgical resection is the mainstay, however is rarely possible due to excessive disease and unresectable nature also from critical structures. As secondary therapies, the literature describes treatment with Adriamycin or radiation. Both scenarios often do not provide adequate treatment. Additionally, with each recurrence, the disease stage advances and is more aggressive.
<u>Optional/General</u> comments		